Complete response of brain metastases to irinotecan-based chemotherapy

Rachel Chou, Allan Chen, Derick H Lau

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.

Original languageEnglish (US)
Pages (from-to)242-245
Number of pages4
JournalJournal of Clinical Neuroscience
Volume12
Issue number3
DOIs
StatePublished - Apr 2005

Fingerprint

irinotecan
Neoplasm Metastasis
Drug Therapy
Brain
Adenocarcinoma
Small Cell Lung Carcinoma
Palliative Care
Radiotherapy

Keywords

  • Brain metastases
  • Irinotecan
  • Whole brain radiation

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology

Cite this

Complete response of brain metastases to irinotecan-based chemotherapy. / Chou, Rachel; Chen, Allan; Lau, Derick H.

In: Journal of Clinical Neuroscience, Vol. 12, No. 3, 04.2005, p. 242-245.

Research output: Contribution to journalArticle

@article{6bd2dd8806d4482ca76ee36605a6b74c,
title = "Complete response of brain metastases to irinotecan-based chemotherapy",
abstract = "Brain metastases occur in 15-20{\%} of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.",
keywords = "Brain metastases, Irinotecan, Whole brain radiation",
author = "Rachel Chou and Allan Chen and Lau, {Derick H}",
year = "2005",
month = "4",
doi = "10.1016/j.jocn.2004.08.007",
language = "English (US)",
volume = "12",
pages = "242--245",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Complete response of brain metastases to irinotecan-based chemotherapy

AU - Chou, Rachel

AU - Chen, Allan

AU - Lau, Derick H

PY - 2005/4

Y1 - 2005/4

N2 - Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.

AB - Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.

KW - Brain metastases

KW - Irinotecan

KW - Whole brain radiation

UR - http://www.scopus.com/inward/record.url?scp=17844383213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844383213&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2004.08.007

DO - 10.1016/j.jocn.2004.08.007

M3 - Article

C2 - 15851073

AN - SCOPUS:17844383213

VL - 12

SP - 242

EP - 245

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 3

ER -